A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia

Antonio C Arrieta, Lillian Sung, John S Bradley, C Michel Zwaan, Davis Gates, Hetty Waskin, Patricia Carmelitano, Andreas H Groll, Thomas Lehrnbecher, Eric Mangin, Amita Joshi, Nicholas A Kartsonis, Thomas J Walsh and Amanda Paschke

PLOS ONE, 2019, vol. 14, issue 3, 1-17

Abstract: Background: Posaconazole (POS) is a potent triazole antifungal agent approved in adults for treatment and prophylaxis of invasive fungal infections (IFIs). The objectives of this study were to evaluate the pharmacokinetics (PK), safety, and tolerability of POS oral suspension in pediatric subjects with neutropenia. Methods: This was a prospective, multicenter, sequential dose-escalation study. Enrolled subjects were divided into 3 age groups: AG1, 7 to

Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0212837 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 12837&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0212837

DOI: 10.1371/journal.pone.0212837

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().